Which has higher earnings & valuation, FLNA or NERV?

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A

Is FLNA or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Minerva Neurosciences N/A N/A -31.72%

Do analysts prefer FLNA or MENS?

Cassava Sciences presently has a consensus price target of $5.00, indicating a potential upside of 488.24%. Given Cassava Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, FLNA or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is FLNA or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Jyong Biotech N/A N/A N/A

Do analysts rate FLNA or SBTX?

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 488.24%. Given Cassava Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, FLNA or SBTX?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is FLNA or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Silverback Therapeutics N/A -29.62% -28.20%

Which has better earnings and valuation, FLNA or NMRA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A

Is FLNA or NMRA more profitable?

Cassava Sciences' return on equity of -58.78% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Neumora Therapeutics N/A -242.28% -131.32%

Does the media prefer FLNA or NMRA?

In the previous week, Cassava Sciences had 4 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Cassava Sciences and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.89 beat Cassava Sciences' score of 0.59 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, FLNA or IMUX?

Immunic is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Immunic N/A N/A -$97.17M -$4.38 N/A

Is FLNA or IMUX more profitable?

Cassava Sciences' return on equity of -58.78% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Immunic N/A -157.89% -107.88%

Does the media refer more to FLNA or IMUX?

In the previous week, Cassava Sciences had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Cassava Sciences and 2 mentions for Immunic. Immunic's average media sentiment score of 1.79 beat Cassava Sciences' score of 0.59 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Cassava Sciences (FLNA) Competitors

$0.85 +0.10 (+13.62%)

As of 04:00 PM Eastern

Compare

FLNA vs. NERV, MENS, SBTX, NMRA, and IMUX

Should you buy Cassava Sciences stock or one of its competitors? Cassava Sciences's main competitors and comparable companies include Minerva Neurosciences (NERV), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), Neumora Therapeutics (NMRA), and Immunic (IMUX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cassava Sciences compare to Minerva Neurosciences?

Cassava Sciences (NASDAQ:FLNA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Cassava Sciences presently has a consensus price target of $5.00, suggesting a potential upside of 488.24%. Minerva Neurosciences has a consensus price target of $10.33, suggesting a potential upside of 203.92%. Given Cassava Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cassava Sciences is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Cassava Sciences had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for Cassava Sciences and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.79 beat Cassava Sciences' score of 0.59 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Positive
Minerva Neurosciences	Very Positive

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

Cassava Sciences has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Minerva Neurosciences	N/A	N/A	-31.72%

Summary

Cassava Sciences beats Minerva Neurosciences on 7 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Jyong Biotech?

Cassava Sciences (NASDAQ:FLNA) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Jyong Biotech's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Jyong Biotech	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

38.1% of Cassava Sciences shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cassava Sciences presently has a consensus price target of $5.00, indicating a potential upside of 488.24%. Given Cassava Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cassava Sciences had 5 more articles in the media than Jyong Biotech. MarketBeat recorded 6 mentions for Cassava Sciences and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.79 beat Cassava Sciences' score of 0.59 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Positive
Jyong Biotech	Very Positive

Cassava Sciences has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

Summary

Cassava Sciences beats Jyong Biotech on 6 of the 11 factors compared between the two stocks.

How does Cassava Sciences compare to Silverback Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Cassava Sciences had 6 more articles in the media than Silverback Therapeutics. MarketBeat recorded 6 mentions for Cassava Sciences and 0 mentions for Silverback Therapeutics. Cassava Sciences' average media sentiment score of 0.59 beat Silverback Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
Silverback Therapeutics	Neutral

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 488.24%. Given Cassava Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silverback Therapeutics' return on equity of -29.62% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Cassava Sciences has a beta of -0.69, meaning that its stock price is 169% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cassava Sciences beats Silverback Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Neumora Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, Cassava Sciences had 4 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Cassava Sciences and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.89 beat Cassava Sciences' score of 0.59 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cassava Sciences is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Cassava Sciences presently has a consensus price target of $5.00, indicating a potential upside of 488.24%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 849.90%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cassava Sciences has a beta of -0.69, meaning that its stock price is 169% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

Cassava Sciences' return on equity of -58.78% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Neumora Therapeutics	N/A	-242.28%	-131.32%

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Neumora Therapeutics beats Cassava Sciences on 9 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Immunic?

Cassava Sciences (NASDAQ:FLNA) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunic is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 488.24%. Immunic has a consensus price target of $47.25, suggesting a potential upside of 396.85%. Given Cassava Sciences' higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Cassava Sciences' return on equity of -58.78% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Immunic	N/A	-157.89%	-107.88%

In the previous week, Cassava Sciences had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Cassava Sciences and 2 mentions for Immunic. Immunic's average media sentiment score of 1.79 beat Cassava Sciences' score of 0.59 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cassava Sciences has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market. Comparatively, Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Summary

Cassava Sciences and Immunic tied by winning 7 of the 14 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.06M	$12.61B	$7.32B	$13.03B
Dividend Yield	N/A	2.62%	2.52%	14.03%
P/E Ratio	-0.98	792.36	275.05	25.61
Price / Sales	N/A	954.00	662.59	108.06
Price / Cash	N/A	15.22	28.02	35.00
Price / Book	0.55	10.63	10.53	6.44
Net Income	-$90.97M	$2.84B	$3.50B	$360.47M
7 Day Performance	14.94%	-1.18%	-1.73%	-1.03%
1 Month Performance	-8.50%	-1.15%	-3.76%	-3.70%
1 Year Performance	-71.57%	1.62%	14.48%	3.62%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.8395 of 5 stars	$0.85 +13.6%	$5.00 +488.2%	-75.0%	$41.06M	N/A	N/A	30	Gap Down High Trading Volume
NERV Minerva Neurosciences	1.8001 of 5 stars	$3.42 +0.6%	$10.33 +202.2%	+60.4%	$164.01M	N/A	N/A	7	Positive News
MENS Jyong Biotech	N/A	$1.99 -2.0%	N/A	-96.6%	$151.22M	N/A	N/A	27	Positive News Gap Up
SBTX Silverback Therapeutics	N/A	$4.08 -1.7%	N/A	-58.4%	$147.12M	N/A	N/A	83	High Trading Volume
NMRA Neumora Therapeutics	3.5646 of 5 stars	$0.74 +9.1%	$6.57 +789.2%	-61.1%	$139.99M	N/A	N/A	63	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. NERV, MENS, SBTX, NMRA, and IMUX

How does Cassava Sciences compare to Minerva Neurosciences?

Summary

How does Cassava Sciences compare to Jyong Biotech?

Summary

How does Cassava Sciences compare to Silverback Therapeutics?

Summary

How does Cassava Sciences compare to Neumora Therapeutics?

Summary

How does Cassava Sciences compare to Immunic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. NERV, MENS, SBTX, NMRA, and IMUX

How does Cassava Sciences compare to Minerva Neurosciences?

Do analysts rate FLNA or NERV?

Does the media prefer FLNA or NERV?

Do institutionals & insiders hold more shares of FLNA or NERV?

Which has higher earnings & valuation, FLNA or NERV?

Which has more risk & volatility, FLNA or NERV?

Is FLNA or NERV more profitable?

Summary

How does Cassava Sciences compare to Jyong Biotech?

Is FLNA or MENS more profitable?

Which has preferable earnings and valuation, FLNA or MENS?

Do institutionals and insiders believe in FLNA or MENS?

Do analysts prefer FLNA or MENS?

Does the media prefer FLNA or MENS?

Which has more risk & volatility, FLNA or MENS?

Summary

How does Cassava Sciences compare to Silverback Therapeutics?

Does the media refer more to FLNA or SBTX?

Do analysts rate FLNA or SBTX?

Is FLNA or SBTX more profitable?

Which has more risk & volatility, FLNA or SBTX?

Which has stronger earnings & valuation, FLNA or SBTX?

Do institutionals & insiders hold more shares of FLNA or SBTX?

Summary

How does Cassava Sciences compare to Neumora Therapeutics?

Does the media prefer FLNA or NMRA?

Which has better earnings and valuation, FLNA or NMRA?

Do analysts rate FLNA or NMRA?

Which has more volatility & risk, FLNA or NMRA?

Is FLNA or NMRA more profitable?

Do institutionals and insiders hold more shares of FLNA or NMRA?

Summary

How does Cassava Sciences compare to Immunic?

Do insiders and institutionals hold more shares of FLNA or IMUX?

Which has better earnings & valuation, FLNA or IMUX?

Do analysts prefer FLNA or IMUX?

Is FLNA or IMUX more profitable?

Does the media refer more to FLNA or IMUX?

Which has more volatility & risk, FLNA or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools